-
Real‐world effectiveness of sodium‐glucose cotransporter‐2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-29 Afif Nakhleh, Muhammad Abdul‐Ghani, Sivan Gazit, Adi Gross, Idit Livnat, Maya Greenbloom, Adva Yarden, Khaled Khazim, Naim Shehadeh, Cheli Melzer Cohen
AimTo examine the renal effects of sodium‐glucose cotransporter‐2 (SGLT2) inhibition among non‐diabetic individuals with chronic kidney disease (CKD) in a real‐world setting.MethodsWe collected de‐identified data on adults without diabetes and with an estimated glomerular filtration rate (eGFR) of 25–60 mL/min/1.73 m2, who initiated the SGLT2 inhibitors dapagliflozin or empagliflozin between September
-
Association of gestational diabetes with long‐term risk of premature mortality, and cardiovascular outcomes and risk factors: A retrospective cohort analysis in the UK Biobank Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-29 Moscho Michalopoulou, Carmen Piernas, Susan A. Jebb, Min Gao, Nerys M. Astbury
AimTo investigate the association of gestational diabetes mellitus (GDM) with premature mortality and cardiovascular (CVD) outcomes and risk factors.Materials and MethodsParous women recruited to the UK Biobank cohort during 2006‐2010 were followed up from their first delivery until 31 October 2021. The data were linked to Hospital Episode Statistics and mortality registries. Multivariate Cox proportional
-
Continuous glucose monitoring for glycaemic control and cardiovascular risk reduction in patients with type 2 diabetes not on insulin therapy: A clinical trial Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-29 Joseph Reed, Tony Dong, Elke Eaton, Janice Friswold, Jodie Porges, Sadeer G. Al‐Kindi, Sanjay Rajagopalan, Ian J. Neeland
AimTo evaluate the impact of the Dexcom G6 continuous glucose monitoring (CGM) device on glycaemic control and cardiometabolic risk in patients with type 2 diabetes mellitus (T2DM) at high cardiovascular risk who are not on insulin therapy.Materials and MethodsAdults with T2DM with glycated haemoglobin (HbA1c) >7% and body mass index (BMI) ≥30 kg/m2 not using insulin were enrolled in a two‐phase cross‐over
-
Body mass index and remote ischaemic conditioning efficacy in acute ischaemic stroke patients: A post hoc analysis of the Remote Ischaemic Conditioning for Acute Moderate Ischaemic Stroke (RICAMIS) trial Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-29 Xiao‐Yu Sun, Hui‐Ling Qu, Hui‐Sheng Chen
-
Once‐weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-29 Richard M. Bergenstal, Athena Philis‐Tsimikas, Carol Wysham, Molly C. Carr, Juliana M. Bue‐Valleskey, Fady T. Botros, Thomas Blevins, Julio Rosenstock
AimsInsulin efsitora alfa (efsitora) is a once‐weekly basal insulin. This review describes the study design and rationale of the efsitora phase 3 Once Weekly (QW) Insulin Therapy (QWINT) clinical development programme, including the five trials, QWINT‐1 through QWINT‐5.Materials and MethodsThe five trials included insulin‐naïve adults (QWINT‐1 and ‐2) with type 2 diabetes (T2D), adults with T2D previously
-
Gamma‐aminobutyric acid supplementation improves olanzapine‐induced insulin resistance by inhibiting macrophage infiltration in mice subcutaneous adipose tissue Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-25 Lulu Ren, Lingling Xuan, Anning Li, Yaqi Yang, Wen Zhang, Jie Zhang, Yi Zhang, Zhuoling An
AimsTo investigate whether gamma‐aminobutyric acid (GABA) supplementation improves insulin resistance during olanzapine treatment in mice and to explore the underlying mechanisms.Materials and MethodsInsulin resistance and body weight gain were induced in mice by 10 weeks of olanzapine treatment. Simultaneously, the mice were administered GABA after 4 weeks of olanzapine administration.ResultsWe found
-
Cross‐sectional, case‐control and longitudinal associations between exposure to glucagon‐like peptide‐1 receptor agonists and the dispensing of antidepressants Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-23 Osvaldo P. Almeida, Zheng Fong, Lydia M. Hill Almeida, Frank M. Sanfilippo, Amy Page, Christopher Etherton‐Beer
AimTo determine if the dispensing of glucagon‐like peptide (GLP)‐1 receptor agonists is associated with increased dispensing of antidepressants.Materials and MethodsWe used cross‐sectional, case‐control and retrospective cohort study designs to examine the association between dispensed GLP‐1 receptor agonists and antidepressants between 2012 and 2022 in the 10% random sample of the Australian Pharmaceutical
-
Biotransformation and disposition characteristics of HSK7653, a novel long‐acting dipeptidyl peptidase‐4 inhibitor for the treatment of type 2 diabetes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-22 Yi‐cong Bian, Jian Meng, Tao Hu, Sheng Ma, Chen‐rong Huang, Feng‐yi Zhang, Qing‐he Wu, Hua Zhang, Xiao‐yan Chen, Li‐yan Miao
AimTo investigate the metabolism and disposition characteristics of HSK7653 in healthy male Chinese participants.MethodsA single oral dose of 80 μCi (25 mg) [14C]HSK7653 capsules was administered to six healthy participants, and blood, plasma, urine and faeces were collected. Quantitative and qualitative analysis was conducted to investigate the pharmacokinetics, blood‐to‐plasma ratio, mass balance
-
Cardiorenal outcomes and mortality after sodium‐glucose cotransporter‐2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-22 Jin Hwa Kim, Young Sang Lyu, BongSeong Kim, Mee Kyung Kim, Sang Yong Kim, Ki‐Hyun Baek, Ki‐Ho Song, Kyungdo Han, Hyuk‐Sang Kwon
AimsTo evaluate the effects of initiating sodium‐glucose cotransporter‐2 (SGLT2) inhibitors on cardiorenal outcomes and mortality compared to dipeptidyl peptidase‐4 (DPP‐4) inhibitors as active comparators in patients diagnosed with type 2 diabetes with a history of percutaneous coronary intervention (PCI).Materials and MethodsWe used an active‐comparator, new‐user design and nationwide data from the
-
C‐peptide index at 2 h post‐meal is a useful predictor of endogenous insulin secretory capacity and withdrawal from insulin therapy in subjects with type 2 diabetes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-22 Yuichiro Iwamoto, Tomohiko Kimura, Masashi Shimoda, Yuichi Morimoto, Yuki Watanabe, Takashi Itoh, Taku Sasaki, Shigehito Mori, Masato Kubo, Haruka Takenouchi, Kazunori Dan, Hideyuki Iwamoto, Junpei Sanada, Yoshiro Fushimi, Yukino Katakura, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
AimsTo evaluate the correlation between C‐peptide index (CPI) at 2 h post‐meal and endogenous insulin secretory capacity and to develop clinical models to predict the possibility of withdrawal from insulin therapy in patients with type 2 diabetes.MethodThis was a single‐centre retrospective study of patients with type 2 diabetes admitted to our hospital. Patients were divided into a withdrawal group
-
Real‐world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12‐month, prospective observational study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-19 Rayaz A. Malik, Chii‐Min Hwu, Anwar A. Jammah, Juan M. Arteaga‐Díaz, Khier Djaballah, Valerie Pilorget, Agustina Alvarez, Carine Vera, Olga Vikulova
AimTo assess the impact of insulin glargine (100 U/mL) and lixisenatide (iGlarLixi) fixed‐ratio combination therapy on the overall management of glycaemia in patients with type 2 diabetes (T2D), previously inadequately controlled with oral antidiabetic drugs ± basal insulin or glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs).Materials and MethodsThis 12‐month, international, multicentre, prospective
-
-
Identification of diagnostic biomarkers used in the diagnosis of cardiovascular diseases and diabetes mellitus: A systematic review of quantitative studies Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-19 Megan Wilson, Abdullah Al‐Hamid, Ismail Abbas, Jason Birkett, Iftikhar Khan, Matthew Harper, Dhiya Al‐Jumeily OBE, Sulaf Assi
AimsTo perform a systematic review of studies that sought to identify diagnostic biomarkers for the diagnosis of cardiovascular diseases (CVDs) and diabetes mellitus (DM), which could be used in low‐ and middle‐income countries (LMICs) where there is a lack of diagnostic equipment, treatments and training.Materials and MethodsPapers were sourced from six databases: the British Nursing Index, Google
-
A meta‐analysis of the association between RBP4 rs3758539 genotype and metabolic syndrome factors Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-19 Wen‐Chieh Wu, Pei‐Yu Wu, Ming‐Fen Lee, Chin‐Ming Chang, Chien‐Yi Chan, Chun‐Yin Huang
AimTo explore the link between the RBP4 rs3758539 genotype and metabolic syndrome risk factors and whether the impact of this genetic variation displays any potential race discrepancy.Materials and MethodsThis meta‐analysis followed the PRISMA guidelines and was registered with PROSPERO (registration no. CRD42023407999). PubMed, Web of Science, Embase, Cochrane Library, Google Scholar, Airiti Library
-
Effectiveness and care continuity in an app‐based, glucagon‐like peptide‐1 receptor agonist‐supported weight‐loss service for women with overweight and obesity in the UK: A real‐world retrospective cohort analysis Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-16 Louis Talay, Matt Vickers
1 BACKGROUND Many digital weight-loss services (DWLSs) have emerged throughout the world in recent years to combat rising obesity rates.1 A key rationale behind digital modalities is that they increase care access, which is a considerable barrier to the treatment of chronic conditions such as obesity, for which patients need to consult with a coordinated multidisciplinary care team (MDT) on an ongoing
-
The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium‐glucose cotransporter‐2 inhibitor, in type 2 diabetes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-15 Sae Im Jeong, Mu Seong Ban, Jun‐Gi Hwang, Min‐Kyu Park, Soo Lim, Sejoong Kim, Soon Kil Kwon, Yoonjin Kim, Jae Min Cho, Jae Jin Na, Wan Huh, Jae‐Yong Chung
AimsTo explore the effect of renal function on the pharmacokinetic (PK) and pharmacodynamic (PD) profile and safety of enavogliflozin, a selective sodium‐glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes mellitus (T2DM).MethodsAn open‐label, two‐part clinical trial was conducted in T2DM patients, stratified by renal function: Group 1, normal renal function; Group 2, mild renal
-
Smoking timing, genetic susceptibility and the risk of incident type 2 diabetes: A cohort study from the UK Biobank Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-15 Ying Hu, Xiang Li, Xuan Wang, Hao Ma, Jian Zhou, Rui Tang, Minghao Kou, Yoriko Heianza, Zhaoxia Liang, Lu Qi
AimTo prospectively assess the association of smoking timing with the risk of type 2 diabetes (T2D) and examine whether smoking amount or genetic susceptibility might modify the relationship.Materials and MethodsA total of 294 815 participants without diabetes from the UK Biobank, including non‐smokers and smokers with data on the time from waking to first cigarette, were included. Cox proportional
-
Time trends and regional variation in utilization of antidiabetic medicines in China, 2015–2022 Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-15 Jieqiong Zhang, Sen Xu, Xingyu Liu, Jinwei Zhang, Shuchen Hu, Xiaoyong Liu, Caijun Yang, Yu Fang
AimTo assess the use of non‐insulin antidiabetic medicines in China.Materials and MethodsWe analysed the national procurement data for 29 non‐insulin antidiabetic medicines from nine subgroups in China from 2015 to 2022. We estimated the number of defined daily doses (DDDs) procured per year in seven regions of China for nine subgroups and adjusted the data by the number of patients with diabetes.
-
The Obese Taste Bud study: Objectives and study design Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-15 Alexander Kersten, Andrea Lorenz, Cita Nottmeier, Michael Schmidt, Anuschka Roesner, Florian Christoph Richter, Kristin Röhrborn, A. Veronica Witte, Sebastian Hahnel, Till Koehne, Matthias Blüher, Michael Stumvoll, Kerstin Rohde‐Zimmermann, Imke Schamarek
AimsTaste modifies eating behaviour, impacting body weight and potentially obesity development. The Obese Taste Bud (OTB) Study is a prospective cohort study launched in 2020 at the University of Leipzig Obesity Centre in cooperation with the HI‐MAG Institute. OTB will test the hypothesis that taste cell homeostasis and taste perception are linked to obesity. Here, we provide the study design, data
-
Prediction of cardiovascular risk factors from retinal fundus photographs: Validation of a deep learning algorithm in a prospective non‐interventional study in Kenya Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-15 Tom White, Viknesh Selvarajah, Fredrik Wolfhagen‐Sand, Nils Svangård, Gayathri Mohankumar, Peter Fenici, Kathryn Rough, Nelson Onyango, Kendall Lyons, Christina Mack, Videlis Nduba, Mansoor Noorali Saleh, Innocent Abayo, Afrah Siddiqui, Malgorzata Majdanska‐Strzalka, Katarzyna Kaszubska, Tove Hegelund‐Myrback, Russell Esterline, Antonio Manzur, Victoria E. R. Parker
AimHypertension and diabetes mellitus (DM) are major causes of morbidity and mortality, with growing burdens in low‐income countries where they are underdiagnosed and undertreated. Advances in machine learning may provide opportunities to enhance diagnostics in settings with limited medical infrastructure.Materials and MethodsA non‐interventional study was conducted to develop and validate a machine
-
Combination of retagliptin and henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, active‐controlled, phase 3 trial Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-15 Yao Wang, Chengxia Jiang, Xiaolin Dong, Mingwei Chen, Qin Gu, Lihui Zhang, Yanqin Fu, Tianrong Pan, Yan Bi, Weihong Song, Jing Xu, WeiPing Lu, Xiaodong Sun, Zi Ye, Danli Zhang, Liang Peng, Xiang Lin, Wei Dai, Quanren Wang, Wenying Yang
AimThis study assessed the efficacy and safety of co‐administering retagliptin and henagliflozin versus individual agents at corresponding doses in patients with type 2 diabetes mellitus who were inadequately controlled with metformin.MethodsThis multicentre, phase 3 trial consisted of a 24‐week, randomized, double‐blind, active‐controlled period. Patients with glycated haemoglobin (HbA1c) levels between
-
Association of single‐point insulin sensitivity estimator index (SPISE) with future cardiovascular outcomes in patients with type 2 diabetes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-15 Simin Deng, Xinqun Hu, Xiangyu Zhang
AimsTo investigate the association of single‐point insulin sensitivity estimator (SPISE) index with future cardiovascular outcomes in patients with type 2 diabetes.Materials and MethodsSPISE index (= 600 × high‐density lipoprotein cholesterol [mg/dL]0.185/triglycerides [mg/dL]0.2 × body mass index [kg/m2]1.338) was calculated in 10 190 participants. Cox proportional hazard regression models were applied
-
Geographic variation in sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-15 Juliana de Oliveira Costa, Jialing Lin, Tamara Y. Milder, Jerry R. Greenfield, Richard O. Day, Sophie L. Stocker, Brendon L. Neuen, Alys Havard, Sallie‐Anne Pearson, Michael O. Falster
AimSodium‐glucose cotransporter 2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) improve glycaemic control and cardio‐renal outcomes for people with type 2 diabetes (T2D). However, geographic and socio‐economic variation in use is not well understood.MethodsWe identified 367 829 New South Wales residents aged ≥40 years who dispensed metformin in 2020 as a proxy for T2D
-
The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-11 Leonardo Buttice, Maryam Ghani, Janahan Suthakar, Sathyan Gnanalingham, Elliott Carande, Brett W. C. Kennedy, Alex Pitcher, James H. P. Gamble, Mahmood Ahmad, Andrew Lewis, Peter Jüni, Oliver J. Rider, Jeffrey W. Stephens, Jonathan J. H. Bray
AimsTo conduct a meta‐analysis of randomized controlled trials (RCTs) to assess the effect of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors on inflammatory biomarkers.MethodsMedline, Embase and the Cochrane Library were searched for RCTs investigating the effect of SGLT2 inhibitors on inflammatory biomarkers, adipokine profiles and insulin sensitivity.ResultsThirty‐eight RCTs were included (14
-
Artificial intelligence‐enhanced electrocardiogram analysis for identifying cardiac autonomic neuropathy in patients with diabetes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-11 Krzysztof Irlik, Hanadi Aldosari, Mirela Hendel, Hanna Kwiendacz, Julia Piaśnik, Justyna Kulpa, Paweł Ignacy, Sylwia Boczek, Mikołaj Herba, Kamil Kegler, Frans Coenen, Janusz Gumprecht, Yalin Zheng, Gregory Y. H. Lip, Uazman Alam, Katarzyna Nabrdalik
AimTo develop and employ machine learning (ML) algorithms to analyse electrocardiograms (ECGs) for the diagnosis of cardiac autonomic neuropathy (CAN).Materials and MethodsWe used motif and discord extraction techniques, alongside long short‐term memory networks, to analyse 12‐lead, 10‐s ECG tracings to detect CAN in patients with diabetes. The performance of these methods with the support vector machine
-
Retagliptin as add‐on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-11 Lixin Guo, Fengsheng Tian, Li Liu, Mingwei Chen, Chengxia Jiang, Shuangqing Li, Cong Liu, Yawei Zhang, Jie Qin, Dongni Yu, Yicen Zong, Wei Dai
AimTo evaluate the efficacy and safety of retagliptin in Chinese patients with type 2 diabetes (T2D) inadequately controlled with metformin.Materials and MethodsThis multicentre, phase 3 trial consisted of a 16‐week, randomized, double‐blind, placebo‐controlled period, where patients with HbA1c levels between 7.5% and 11.0% were randomized to receive either once‐daily (QD) retagliptin 100 mg (n = 87)
-
Real‐world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-11 Lixin Guo, Yue Xi, Li Li, Kunquan Guo, Jun Wu, Jiawei Xu, Yihua Wang, Guangyu Wu, Si Si
CONFLICT OF INTEREST STATEMENT Lixin Guo is on the advisory boards/consultant for Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Dreisamtech, Dongbao, Eli Lilly, Gan & Lee, Hansoh, Hengrui, Hua Medicine, Huadong Medicine, Innovent Bio, Janssen, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi, Synapsor, Takeda, Zense and 3SBIO. Lixin Guo received funding from National Natural Science Foundation of
-
Safety and efficacy of teplizumab in the treatment of type 1 diabetes mellitus: An updated systematic review and meta‐analysis of randomized controlled trials Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-11 Gabriel Grando Alves, Luisa Cunha, Rafael Henkes Machado, Vanessa Lins de Menezes
AimTo provide updated efficacy and safety information for teplizumab in the treatment of Stage 3 type 1 diabetes mellitus (T1DM).Materials and MethodsThe PubMed, Embase and Cochrane databases were searched for randomized controlled trials (RCTs) comparing teplizumab to placebo for T1DM that reported any of the following outcomes: (1) C‐peptide area under the curve (AUC); (2) glycated haemoglobin (HbA1c)
-
Healthy Outcomes through Peer Educators: Feasibility of a peer support diabetes prevention programme for African-American grandmother caregivers Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-03 Eva M. Vivian, Betty A. Chewning, Corrine I. Voils, Roger L. Brown
To assess the protocol feasibility and intervention acceptability of a community-based, peer support diabetes prevention programme (DPP) for African-American (AA) grandmother caregivers at risk for diabetes.
-
-
Sleep duration and association with cardiometabolic health in adolescents and adults with type 1 diabetes: Results from the BCQR‐T1D study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-08 Stacey L. Simon, Janet K. Snell‐Bergeon, Michal Schäfer, Alex J. Barker, Lorna P. Browne, Uyen Truong, Shoshana S. Tell, Timothy Vigers, Amy D. Baumgartner, Ellen Lyon, Sarit Polsky, Irene E. Schauer, Kristen J. Nadeau
AimType 1 diabetes (T1D) increases the risk of morbidity and mortality from cardiovascular disease, and insufficient sleep is prevalent. Emerging evidence suggests a link between sleep and cardiometabolic health, but this has not been examined across the lifespan in individuals with T1D. We aimed to examine associations between sleep and cardiometabolic health in adolescents and adults with T1D in
-
Prediction of new‐onset heart failure in patients with type 2 diabetes derived from ALTITUDE and CANVAS Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-08 Fatema Said, Clare Arnott, Adriaan A. Voors, Hiddo J. L. Heerspink, Jozine M. ter Maaten
AimTo create and validate a prediction model to identify patients with type 2 diabetes (T2D) at high risk of new‐onset heart failure (HF), including those treated with a sodium‐glucose cotransporter‐2 (SGLT2) inhibitor.MethodsA prediction model was developed from the Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints (ALTITUDE), a trial in T2D patients with albuminuria or cardiovascular
-
Effects of high‐dose versus standard‐dose quadrivalent influenza vaccine among patients with diabetes: A post‐hoc analysis of the DANFLU‐1 trial Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-08 Mats C. Højbjerg Lassen, Niklas Dyrby Johansen, Daniel Modin, Joshua Nealon, Sandrine Samson, Marine Dufournet, Matthew M. Loiacono, Carsten Schade Larsen, Anne Marie Reimer Jensen, Nino Emanuel Landler, Brian L. Claggett, Scott D. Solomon, Martin J. Landray, Gunnar H. Gislason, Lars Køber, Jens Ulrik Stæhr Jensen, Pradeesh Sivapalan, Lasse Skafte Vestergaard, Tyra Grove Krause, Tor Biering‐Sørensen
AimHigh‐dose quadrivalent influenza vaccine (QIV‐HD) has been shown to be more effective than standard‐dose (QIV‐SD) in reducing influenza infection, but whether diabetes status affects relative vaccine effectiveness (rVE) is unknown. We aimed to assess rVE on change in glycated haemoglobin [HbA1c (∆HbA1c)], incident diabetes, total all‐cause hospitalizations (first + recurrent), and a composite of
-
A comment on ‘Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials’ Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-05 Ronald M. Goldenberg
-
Improved glycaemic control induced by evening activity breaks does not persist overnight amongst healthy adults: A randomized crossover trial Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-04 Jennifer T. Gale, Jillian J. Haszard, Meredith C. Peddie
AimsTo compare the effects of 4 hours of laboratory‐based regular activity breaks (RABs) and prolonged sitting (SIT) on subsequent 48‐h free‐living interstitial glucose levels in a group of healthy adults.Materials and MethodsIn this randomized crossover trial, participants completed two 4‐h laboratory‐based interventions commencing at ~5:00 pm: (1) SIT and (2) SIT interrupted with 3 min of body weight
-
Dual glucagon‐like peptide‐1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-02 Rajna Golubic, Jane Kennet, Victoria Parker, Darren Robertson, Dan Luo, Lars Hansen, Lutz Jermutus, Phil Ambery, Maria Ryaboshapkina, Manasa Surakala, Rhianna C. Laker, Michelle Venables, Albert Koulman, Adrian Park, Mark Evans
AimsTo establish which components of energy balance mediate the clinically significant weight loss demonstrated with use of cotadutide, a glucagon‐like peptide‐1 (GLP‐1)/glucagon receptor dual agonist, in early‐phase studies.Materials and MethodsWe conducted a phase 2a, single‐centre, randomized, placebo‐controlled trial in overweight and obese adults with type 2 diabetes. Following a 16‐day single‐blind
-
Short, frequent, light‐intensity walking activity improves postprandial vascular‐inflammatory biomarkers in people with type 1 diabetes: The SIT‐LESS randomized controlled trial Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-01 Nawaz Z. Safdar, Anwar M. Alobaid, Mark Hopkins, Paddy C. Dempsey, Sam M. Pearson, Noppadol Kietsiriroje, Rachel Churm, Ramzi A. Ajjan, Matthew D. Campbell
AimTo examine the effect of interrupting prolonged sitting with short, frequent, light‐intensity activity on postprandial cardiovascular markers in people with type 1 diabetes (T1D).Materials and MethodsIn a randomized crossover trial, 32 adults with T1D (mean ± SD age 28 ± 5 years, glycated haemoglobin 67.9 ± 12.6 mmol/mol, 17 women) completed two 7‐h laboratory visits separated by >7 days. Participants
-
Combined intake of caffeine and low‐dose glucose to reduce exercise‐related hypoglycaemia in individuals with type 1 diabetes on ultra‐long‐acting insulin degludec: A randomized, controlled, double‐blind, cross‐over trial Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-01 Tobias Kühne, Esmè Wallace, David Herzig, Simon Helleputte, Sam Scott, Jordan Pickles, Andreas Melmer, Christoph Stettler
AimTo evaluate whether caffeine combined with a moderate amount of glucose reduces the risk for exercise‐related hypoglycaemia compared with glucose alone or control in adult people with type 1 diabetes using ultra‐long‐acting insulin degludec.Materials and MethodsSixteen participants conducted three aerobic exercise sessions (maximum 75 min) in a randomized, double‐blind, cross‐over design. Thirty
-
Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR‐Pooled analysis Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-01 Khawaja M. Talha, Jennifer Green, Gerasimos Filippatos, Stuart Pocock, Faiez Zannad, Martina Brueckmann, Elke Schueler, Anne Pernille Ofstad, João Pedro Ferreira, Stefan D. Anker, Javed Butler, Julio Rosenstock, Milton Packer
AimTo assess the effect of empagliflozin on patients with comorbid heart failure (HF) and diabetes with or without baseline insulin, and to study the impact of empagliflozin on insulin requirements over time.Materials and MethodsWe performed a post‐hoc analysis of pooled patient‐level data from two cardiovascular outcomes trials of empagliflozin in HF (EMPEROR‐Reduced and EMPEROR‐Preserved trials)
-
Evaluating the global impact of low physical activity on type 2 diabetes: Insights from the global burden of disease 2019 study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-01 Juan Luo, Xinlan Zhao, Qianru Li, Binbin Zou, Wen Xie, Yanjun Lei, Jinglin Yi, Chi Zhang
AimWe aimed to assess the global implications of low physical activity (LPA) on type 2 diabetes mellitus (T2DM) by utilizing data from the Global Burden of Disease (GBD) 2019.MethodsThe analysis was conducted by examining the age‐standardized disability‐adjusted life years (DALYs) rates over a 30‐year period. To assess the trends, we utilized estimated annual percentage changes (EAPCs).ResultsThe study
-
Effect of combination pioglitazone with sodium‐glucose cotransporter‐2 inhibitors or glucagon‐like peptide‐1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta‐analysis, and real‐world study from an international federated database Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-01 Matthew Anson, Alex E. Henney, Sizheng S. Zhao, Gema H. Ibarburu, Gregory Y. H. Lip, Daniel J. Cuthbertson, Katarzyna Nabrdalik, Uazman Alam
AimsTo evaluate the efficacy and cardiovascular outcomes of combination pioglitazone with either a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) or a sodium‐glucose cotransporter‐2 (SGLT2) inhibitor in individuals with type 2 diabetes (T2D) by conducting a systematic review, meta‐analysis, and analysis of a large international real‐world database.MethodsWe searched MEDLINE, SCOPUS and Web of Science
-
The need for registry-based studies in diabetes and stroke: A unique opportunity to understand whether diabetic treatments improve post-stroke outcome Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-01 Vladimer Darsalia, Ellen Vercalsteren, Dimitra Karampatsi, Mihaela Oana Romanitan, Michael V. Mazya, Thomas Nyström, Cesare Patrone
1 ISCHAEMIC STROKE OUTCOME, DISABILITY AND TREATMENTS Despite significant improvements in acute stroke management, stroke is still the second world-leading cause of death (6.6 million people) and the third world-leading cause of disability (143 million disability-adjusted life years lost).1 Therapies to improve outcomes after ischaemic stroke are currently exclusively based on successful thrombolysis
-
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-01 Elena A. Christofides, Orlando Puente, Paul Norwood, Douglas Denham, Hiralal Maheshwari, Michael Lillestol, Terence Hart, Samer Nakhle, Anurekha Chadha, David Fitz‐Patrick, Danny Sugimoto, Joseph Soufer, Douglas Young, Mark Warren, David Huffman, John Reed, Harold Bays, Samir Arora, Barbara Rizzardi, Raymond Tidman, Marc Rendell, Kimball A. Johnson
AimTo evaluate the equivalence of immunogenicity, safety and efficacy of Gan & Lee (GL) Glargine (Basalin®; Gan & Lee Pharmaceutical) with that of the reference product (Lantus®) in adult participants with type 2 diabetes mellitus.MethodsThis was a phase 3, multicenter, open‐label, equivalence trial conducted across 57 sites. In total, 567 participants with type 2 diabetes mellitus were randomized
-
Risk of lower extremity amputation in patients with type 2 diabetes mellitus and peripheral arterial disease receiving sodium‐glucose cotransporter‐2 inhibitors versus other medications: A systematic review and meta‐analysis of observational cohort studies Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-01 Anna Hodgson, Clare L. Gillies, Patrick Highton, Louise Haddon, Safoora Gharibzadeh, Francesco Zaccardi, Kamlesh Khunti
1 BACKGROUND Type 2 diabetes mellitus (T2DM) is associated with significant microvascular and macrovascular complications, leading to an increased risk of morbidity and mortality. Advancement in the treatment of T2DM has led to the development of novel therapies, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors, which have been shown to significantly reduce adverse health outcomes.1 A recent
-
The dual GCGR/GLP‐1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-01 Leo Thomas, Eric Martel, Wolfgang Rist, Ingo Uphues, Dieter Hamprecht, Heike Neubauer, Robert Augustin
AimTo describe the biomarker strategy that was applied to select survodutide (BI 456906), BI 456908 and BI 456897 from 19 dual glucagon receptor (GCGR)/ glucagon‐like peptide‐1 receptor (GLP‐1R) agonists for in‐depth pharmacological profiling, which led to the qualification of survodutide as the clinical development candidate.Materials and MethodsPotencies to increase cyclic adenosine monophosphate
-
Cardiovascular health metrics defined by Life's Essential 8 scores and subsequent macrovascular and microvascular complications in individuals with type 2 diabetes: A prospective cohort study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-01 Ze‐Gui Huang, Jing‐Wei Gao, Hai‐Feng Zhang, Si You, Zhuo‐Chao Xiong, Yu‐Biao Wu, Da‐Chuan Guo, Jing‐Feng Wang, Yang‐Xin Chen, Shao‐Ling Zhang, Pin‐Ming Liu
AimTo investigate the association between cardiovascular health metrics defined by Life's Essential 8 (LE8) scores and vascular complications among individuals with type 2 diabetes (T2D).Materials and MethodsThis prospective study included 11 033 participants with T2D, all devoid of macrovascular diseases (including cardiovascular and peripheral artery disease) and microvascular complications (e.g
-
An update review of post‐transplant diabetes mellitus: Concept, risk factors, clinical implications and management Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-01 Mehmet Kanbay, Sidar Copur, A. Umur Topçu, Mustafa Guldan, Lasin Ozbek, Abduzhappar Gaipov, Charles Ferro, Mario Cozzolino, David Z. I. Cherney, Katherine R. Tuttle
ObjectiveKidney transplantation is the gold standard therapeutic alternative for patients with end‐stage renal disease; nevertheless, it is not without potential complications leading to considerable morbidity and mortality such as post‐transplant diabetes mellitus (PTDM). This narrative review aims to comprehensively evaluate PTDM in terms of its diagnostic approach, underlying pathophysiological
-
Patterns of initial and first‐intensifying antidiabetic drug utilization among patients with type 2 diabetes mellitus in Scotland, 2010–2020: A retrospective population‐based cohort study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-01 Fatema Mahmoud, Tanja Mueller, Alexander Mullen, Christopher Sainsbury, Gordon F. Rushworth, Amanj Kurdi
AimTo evaluate the utilization and prescribing patterns of antidiabetic drugs (ADDs) for patients with type 2 diabetes mellitus (T2DM) at treatment initiation and first intensification.MethodsA retrospective cohort study was performed using linked routinely collected data of patients with T2DM who received ADDs between January 2010 and December 2020 in Scotland. The prescribing patterns were quantified
-
Differential effect of endogenous glucagon‐like peptide‐1 on prandial glucose counterregulatory response to hypoglycaemia in humans with and without bariatric surgery Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-04-01 Henri Honka, Amalia Gastaldelli, Samantha Pezzica, Richard Peterson, Ralph DeFronzo, Marzieh Salehi
AimTo determine the effect of endogenous glucagon‐like peptide 1 (GLP‐1) on prandial counterregulatory response to hypoglycaemia after gastric bypass (GB).Materials and MethodsGlucose fluxes, and islet‐cell and gut hormone responses before and after mixed‐meal ingestion, were compared during a hyperinsulinaemic‐hypoglycaemic (~3.2 mmol/L) clamp with and without a GLP‐1 receptor (GLP‐1R) antagonist
-
Correction to ‘In people with type 2 diabetes, sarcopenia is associated with the incidence of cardiovascular disease: A prospective cohort study from the UK Biobank’ Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-27
Boonpor, J, Pell, JP, Ho, FK, Celis-Morales, C, Gray, SR. In people with type 2 diabetes, sarcopenia is associated with the incidence of cardiovascular disease: A prospective cohort study from the UK Biobank. Diabetes Obes Metab. 2024; 26(2): 524–531. doi:10.1111/dom.15338 In references 23 and 25, the authors' first names have been used instead of their last names. The correct references 23 and 25
-
TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-27 Snežana Milanović, Nina Dedic, Robert Lew, Duane Burton, Kenneth S. Koblan, Michael Camilleri, Seth C. Hopkins
BackgroundMetabolic syndrome (MetS), which can be induced or exacerbated by the current class of antipsychotic drugs, is highly prevalent in patients with schizophrenia and presents significant challenges to lifetime disease management. Supported by initial clinical results, trace amine‐associated receptor 1 (TAAR1) agonists have emerged as potential novel treatments for schizophrenia. Notably, non‐clinical
-
-
Comparison of estimated glomerular filtration rate change with sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists among people with diabetes: A propensity‐score matching study Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-26 Yuta Suzuki, Hidehiro Kaneko, Hajime Nagasawa, Akira Okada, Katsuhito Fujiu, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Akira Nishiyama, Tomohito Gohda, Yusuke Suzuki, Koichi Node, Hideo Yasunaga, Masaomi Nangaku, Issei Komuro
AimTo compare the risk of developing kidney outcomes with use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) versus use of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors among individuals with diabetes.Materials and MethodsIn this retrospective observational study, we analysed 12 338 individuals with diabetes who newly initiated SGLT2 inhibitors or GLP‐1RAs using data from the JMDC claims
-
Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-26 Bertrand Cariou, Jennifer Linge, Ian J. Neeland, Olof Dahlqvist Leinhard, Mikael Petersson, Laura Fernández Landó, Ross Bray, Ángel Rodríguez
AimsTo describe the overall fat distribution patterns independent of body mass index (BMI) in participants with type 2 diabetes (T2D) in the SURPASS‐3 MRI substudy by comparison with sex‐ and BMI‐matched virtual control groups (VCGs) derived from the UK Biobank imaging study at baseline and Week 52.MethodsFor each study participant at baseline and Week 52 (N = 296), a VCG of ≥150 participants with
-
Intra‐pancreatic fat is associated with continuous glucose monitoring metrics Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-26 Yutong Liu, Wandia Kimita, Xiatiguli Shamaitijiang, Loren Skudder‐Hill, Ivana R. Sequeira‐Bisson, Maxim S. Petrov
AimTo investigate the relationship of fat in the pancreas with time spent in different glycaemic ranges.MethodsAbdominal magnetic resonance imaging at 3.0 Tesla was used to quantify fat in the pancreas as both continuous [i.e. intra‐pancreatic fat deposition (IPFD)] and binary (i.e. fatty change of the pancreas vs. normal pancreas) variables. Dexcom G6 devices were used to collect continuous glucose
-
Maladaptive response following glucose overload in GLUT4‐overexpressing H9C2 cardiomyoblasts Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-26 Bernd Stratmann, Britta Eggers, Yvonne Mattern, Tayana Silva de Carvalho, Katrin Marcus‐Alic, Diethelm Tschoepe
BackgroundGlucose overload drives diabetic cardiomyopathy by affecting the tricarboxylic acid pathway. However, it is still unknown how cells could overcome massive chronic glucose influx on cellular and structural level.Methods/MaterialsExpression profiles of hyperglycemic, glucose transporter‐4 (GLUT4) overexpressing H9C2 (KE2) cardiomyoblasts loaded with 30 mM glucose (KE230L) and wild type (WT)
-
The effect of glucagon‐like peptide‐1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta‐analysis Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-26 Yu Zhang, Danning Yang, Qiufeng Jia, Jie Yan, Fengshuang An
AimsTo conduct an updated systematic review and meta‐analysis to evaluate the efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) with regard to cardiac function and structure in people with or without type 2 diabetes mellitus (T2DM).Materials and MethodsWe conducted a systematic search using the PubMed, Embase and ClinicalTrials.gov online databases. The primary outcome of interest was
-
The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through ‘stacking’ of drugs from different classes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-22 David S. H. Bell, Terri Jerkins
Aggressive therapy of diabetic kidney disease (DKD) can not only slow the progression of DKD to renal failure but, if utilized at an early enough stage of DKD, can also stabilize and/or reverse the decline in renal function. The currently recognized standard of therapy for DKD is blockade of the renin‐angiotensin system with angiotensin‐converting enzyme (ACE) inhibitors or angiotensin II receptor
-
During an 18‐month course of automated insulin delivery treatment, children aged 2 to 6 years achieve and maintain a higher time in tight range Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-22 Mari‐Anne Pulkkinen, Tero J. Varimo, Elina T. Hakonen, Matti T. Hero, Päivi J. Miettinen, Anna‐Kaisa Tuomaala
AimsTo investigate whether the positive effects on glycaemic outcomes of 3‐month automated insulin delivery (AID) achieved in 2‐ to 6‐year‐old children endure over an extended duration and how AID treatment affects time in tight range (TITR), defined as 3.9–7.8 mmol/L.Research Design and MethodsWe analysed 18 months of follow‐up data from a non‐randomized, prospective, single‐arm clinical trial (n
-
Practical strategies to manage obesity in type 2 diabetes Diabetes Obes. Metab. (IF 5.8) Pub Date : 2024-03-22 Helena W. Rodbard, Katharine Barnard‐Kelly, Andreas F. H. Pfeiffer, Carina Mauersberger, Oliver Schnell, Francesco Giorgino
The rising phenomenon of obesity, a major risk factor for the development and progression of type 2 diabetes, is a complex and multifaceted issue that requires a comprehensive and coordinated approach to be prevented and managed. Although novel pharmacological measures to combat obesity have achieved unprecedented efficacy, a healthy lifestyle remains essential for the long‐term success of any therapeutic